<DOC>
	<DOCNO>NCT01338883</DOCNO>
	<brief_summary>This randomize , double-blind , double-dummy , 48-week , comparative study . Approximately 150 HIV-infected , treatment-naïve patient CCR5-tropic virus stratify HIV-1 RNA : ≥100,000 copies/mL versus &lt; 100,000 copies/mL randomize 2:2:1 receive : - Arm A : CVC 100 mg ( 2 tablet , 50 mg ) QD + CVC match placebo ( 2 tablet ) QD + EFV match placebo ( 1 tablet ) QHS + FTC/TDF ( 1 tablet ) QD . - Arm B : CVC 200 mg ( 4 tablet , 50 mg ) QD + EFV match placebo ( 1 tablet ) QHS + FTC/TDF ( 1 tablet ) QD . - Arm C : CVC match placebo ( 4 tablet ) QD + EFV 600 mg ( 1 tablet ) QHS + FTC/TDF ( 1 tablet ) QD . Doses CVC/placebo EFV/ placebo administer double-blinded study drug . FTC/TDF administer open-label study drug fixed-dose combination formulation ( Truvada ) . CVC/placebo take follow breakfast ; EFV take empty stomach bedtime . HIV-1 RNA level CD4+ CD8+ cell count , percentage , ratio measure every visit . Samples viral tropism resistance test case virologic failure collect Screening on-treatment visit . Biomarkers associated inflammation immune activation measure Baseline ( predose ) study visit thereafter , flow cytometry obtain week 4 , 12 , 24 , 48 , 52 . Fasting metabolic indicator glucose control ( glucose insulin HOMA-IR , HbA1c ) fast lipid profile ( HDL , LDL , total cholesterol , triglyceride ) measure Baseline ( predose ) Weeks 4 , 12 , 24 , 48 , 52 . Waist-to-hip ratio measure Baseline Weeks 24 48 . Plasma sample collect store possible future study Baseline ( predose ) every visit thereafter .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Cenicriviroc ( CVC ) Combination With Truvada Sustiva Plus Truvada HIV 1-infected , Antiretroviral Treatment-naïve , Adult Patients Infected With Only CCR5-tropic Virus</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>Selected 1 . Adult male female , HIV1infected patient 18 year old old . 2 . Body mass index ( BMI ) 18 &lt; 35 kg/m2 . 3 . Antiretroviral treatmentnaïve . Treatmentnaïve define : No prior nonnucleoside reverse transcriptase inhibitor , woman receive single dose perinatal nevirapine K103 viral mutation . No prior CCR5 antagonist therapy . No 10 day prior antiretroviral therapy . 4 . HIV1 CCR5tropiconly virus . 5 . Plasma HIV1 RNA level &gt; /=1,000 copies/mL first Screening . 6 . CD4 cell count &gt; /=250 cells/mm3 first Screening . Selected 1 . Presence CXCR4 dual/mixedtropic HIV1 virus . 2 . Presence primary resistance mutation phenotypic resistance TDF , FTC , EFV and/or mutation associate multidrug nucleoside/nucleotide resistance . 3 . An active CDC category C disease ( except cutaneous Kaposi 's sarcoma require systemic therapy trial ) . 4 . Any historical CD4 count &lt; 200 cells/mm3 . 5 . Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value Grade &gt; 2 total bilirubin great upper limit normal ( ULN ) . 6 . History HIV2 , hepatitis B and/or C , cirrhosis liver , know active chronic liver disease . Hepatitis B vaccinate patient eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV-1 Infection</keyword>
	<keyword>CCR5-tropic</keyword>
	<keyword>Anti-retroviral naive</keyword>
</DOC>